Sofia, October 5, 2022 – Nedelko Nedelkov, MPharm and Chief Expert in HTA for the National Council on Prices and Reimbursement of Medicinal Products in Bulgaria presented one of the core activities of the Council, which is monitoring the therapeutic effect of medicinal products with a new International Non-proprietary Name (INN), included in the Positive Drug List. This approach is fully based on aggregated and de-identified real-world data.

Danny Platform is the software used to provide the National Council with real-world evidence to evaluate the effectiveness of innovative medicinal products. This is a fundamental, new, innovative and technology-driven process not only for Bulgaria, but also for European countries in general and the National Council is extremely proud to be on the right path.

“Today payers and health authorities are looking for ways to incorporate data-driven, analytics platforms to utilize Big Data to evaluate efficacy, effectiveness, and outcomes for both review of new indications and post-approval studies. The National Council has achieved a great progress into this direction bringing the outcome-based approach to life”, said Nedelko Nedelkov.

Danny Platform employs advanced analytics and AI to address the gap of turning data into action, give insight about new therapies and scale the ability to address current healthcare needs.

Via Danny Platform, the National Council centralizes and manages population health data, and identifies necessary steps to navigate the transition to value-based care.